Post by ProBioGen AG

📣 ProBioGen Appoints Simon Johannes Bulling, PhD as Chief Operating Officer We are pleased to announce the appointment of Dr. Simon Bulling as Chief Operating Officer (COO), effective April 15, 2026. In this role, Dr. Bulling will lead ProBioGen's operational business and oversee the manufacturing of biologics across the company's growing portfolio — spanning proteins, viral vectors, and cell and gene therapy — further strengthening ProBioGen's position as a trusted partner in the global biopharmaceutical industry. Dr. Alfred Merz, Chief Executive Officer of ProBioGen, commented: "Simon brings a proven track record of scaling complex manufacturing organizations and delivering at both clinical and commercial scale — precisely the experience this next stage of ProBioGen's development calls for. I am delighted to welcome him and look forward to the contribution he will make to our partners and to ProBioGen." We welcome Dr. Bulling to the ProBioGen leadership team and look forward to what we will build together! 🔗Read the full press release: https://lnkd.in/d9XRKE4f #PressRelease #ProBioGen #BiopharmaNews